Moderna’s Lofty Aims To Prevent Diseases With Pandemic Potential

Plans Vaccines For 15 'Priority Pathogens'

The biotech has 15 pathogens in its sights and is also launching mRNA Access that will grant researchers the opportunity to use Moderna's technology platform to develop vaccines for emerging or neglected infectious diseases.

• Source: Archive

Hoping to repeat the success of its mRNA-based COVID-vaccine, Moderna, Inc. has unveiled plans to advance a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases into clinical studies by 2025.

The biotech will target the "15 priority pathogens" deemed by the World Health Organization (WHO) and the Coalition for Epidemic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.